saccharomyces boulardii and Improved Left Ventricular Ejection Fraction

• Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial.

  • 2021-08
  • RCT · n = 151
  • EBioMedicine 70
  • • Ayodeji Awoyemi
    • Cristiane Mayerhofer
    • Alex S Felix
    • Johannes R Hov
    • Samuel D Moscavitch
    • Knut Tore Lappegård
    • Anders Hovland
    • Sigrun Halvorsen
    • Bente Halvorsen
    • Ida Gregersen
    • Asbjørn Svardal
    • Rolf K Berge
    • Simen H Hansen
    • Alexandra Götz
    • Kristian Holm
    • Pål Aukrust
    • Sissel Åkra
    • Ingebjørg Seljeflot
    • Svein Solheim
    • Andrea Lorenzo
    • Lars Gullestad
    • Marius Trøseid
    • Kaspar Broch

  • PubMed: 34329947
  • DOI: 10.1016/j.ebiom.2021.103511

  4 Insights on

  • Improved Left Ventricular Ejection Fraction

  • High evidence
  • Large Human Trial
  • Clinical

  After three months' treatment, the LVEF did not differ significantly between the SoC arm and the Saccharomyces boulardii arm (mean difference -0•2 percentage points; 95% CI -2•2 - 1•9; p=0•87).

  Effect

  Neutral

  Effect size

  Small

  Significant

  No